Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.

Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA, Gingras MC.

Cancer. 2011 Jul 1;117(13):2863-72. doi: 10.1002/cncr.25858. Epub 2011 Jan 10.


The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function.

Zhou G, Gingras MC, Liu SH, Li D, Li Z, Catania RL, Stehling KM, Li M, Paganelli G, Gibbs RA, Demayo FJ, Fisher WE, Brunicardi FC.

World J Surg. 2011 Aug;35(8):1715-24. doi: 10.1007/s00268-010-0939-9.


SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes.

Zhou G, Gingras MC, Liu SH, Sanchez R, Edwards D, Dawson D, Christensen K, Paganelli G, Gibbs R, Fisher W, Brunicardi FC.

Surgery. 2011 Dec;150(6):1136-42. doi: 10.1016/j.surg.2011.09.044.


Case-control study of diabetes-related genetic variants and pancreatic cancer risk in Japan.

Kuruma S, Egawa N, Kurata M, Honda G, Kamisawa T, Ueda J, Ishii H, Ueno M, Nakao H, Mori M, Matsuo K, Hosono S, Ohkawa S, Wakai K, Nakamura K, Tamakoshi A, Nojima M, Takahashi M, Shimada K, Nishiyama T, Kikuchi S, Lin Y.

World J Gastroenterol. 2014 Dec 14;20(46):17456-62. doi: 10.3748/wjg.v20.i46.17456.


Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer.

Wang L, Miao X, Tan W, Lu X, Zhao P, Zhao X, Shan Y, Li H, Lin D.

Clin Gastroenterol Hepatol. 2005 Aug;3(8):743-51.


Association of thymidylate synthase and hypoxia inducible factor-1alpha DNA polymorphisms with pancreatic cancer.

Ruiz-Tovar J, Fernandez-Contreras ME, Martín-Perez E, Gamallo C.

Tumori. 2012 May-Jun;98(3):364-9. doi: 10.1700/1125.12406.


Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer.

Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3467-73. doi: 10.1158/1055-9965.EPI-08-0514.


Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.

Chen J, Li D, Killary AM, Sen S, Amos CI, Evans DB, Abbruzzese JL, Frazier ML.

Ann Surg Oncol. 2009 Feb;16(2):431-9. doi: 10.1245/s10434-008-0220-8. Epub 2008 Nov 20.


Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.

Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D.

Clin Cancer Res. 2010 Jan 1;16(1):320-9. doi: 10.1158/1078-0432.CCR-09-1555. Epub 2009 Dec 22.


Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly.

Ciganoka D, Balcere I, Kapa I, Peculis R, Valtere A, Nikitina-Zake L, Lase I, Schiöth HB, Pirags V, Klovins J.

Eur J Endocrinol. 2011 Oct;165(4):517-25. doi: 10.1530/EJE-11-0416. Epub 2011 Aug 2.


Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer.

Dong X, Tang H, Hess KR, Abbruzzese JL, Li D.

Cancer. 2011 Feb 1;117(3):480-91. doi: 10.1002/cncr.25612. Epub 2010 Sep 15.


Genetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California.

Duell EJ, Holly EA, Kelsey KT, Bracci PM.

Int J Cancer. 2010 Feb 1;126(3):790-5. doi: 10.1002/ijc.24792.


Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma.

Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA.

Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):726-31.


Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer.

Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D.

Gastroenterology. 2010 Aug;139(2):464-73, 473.e1-3. doi: 10.1053/j.gastro.2010.04.042. Epub 2010 Apr 21.


Effects of base excision repair gene polymorphisms on pancreatic cancer survival.

Li D, Li Y, Jiao L, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL.

Int J Cancer. 2007 Apr 15;120(8):1748-54.


Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: a possible role of nucleophosmin.

Zhao D, Xu D, Zhang X, Wang L, Tan W, Guo Y, Yu D, Li H, Zhao P, Lin D.

Gastroenterology. 2009 May;136(5):1659-68.


Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk.

Jang JH, Cotterchio M, Borgida A, Liu G, Gallinger S, Cleary SP.

Mol Carcinog. 2013 Nov;52 Suppl 1:E103-9. doi: 10.1002/mc.22037. Epub 2013 Jun 12.


A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.

Smith JP, Harms JF, Matters GL, McGovern CO, Ruggiero FM, Liao J, Fino KK, Ortega EE, Gilius EL, Phillips JA 3rd.

Cancer Biol Ther. 2012 Feb 1;13(3):164-74. doi: 10.4161/cbt.13.3.18698. Epub 2012 Feb 1.


The functional cytotoxic T lymphocyte-associated Protein 4 49G-to-A genetic variant and risk of pancreatic cancer.

Yang M, Sun T, Zhou Y, Wang L, Liu L, Zhang X, Tang X, Zhou M, Kuang P, Tan W, Li H, Yuan Q, Yu D.

Cancer. 2012 Oct 1;118(19):4681-6. doi: 10.1002/cncr.27455. Epub 2012 Feb 22.


Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.

Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D.

Clin Cancer Res. 2008 Apr 1;14(7):2042-8. doi: 10.1158/1078-0432.CCR-07-1520.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk